Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the U.S. Food and Drug Administration to reduce certain risks associated with ...

Pegcetacoplan is the first FDA-approved treatment for C3G and primary IC-MPGN, targeting excessive C3 complement activation. The phase 3 VALIANT trial showed a 68% reduction in UPCR and stabilization ...

Novartis and its Fabhalta may have been first to the punch in ultrarare kidney disease complement 3 glomerulopathy (C3G), but Apellis Pharmaceuticals has delivered a checkmate with a wider label and a ...

The US Food and Drug Administration (FDA) has instructed all GLP-1 drug-makers to update their warning labels to include the risk of serious kidney injury that can result from dehydration. This comes ...